Skip to search formSkip to main contentSkip to account menu

ALX-0081

Known as: ALX 0081, ALX0681, ALX0081 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Designing alloys with an accurate temperature‐independent electrical response over a wide temperature range, specifically a low… 
2017
2017
All-solid-state lithium batteries offer notable advantages over conventional Li-ion batteries with liquid electrolytes in terms… 
Review
2013
Review
2013
This manuscript reviews the studies performed with ALX-0081 (INN: caplacizumab), a Nanobody targeting von Willebrand factor, in… 
Highly Cited
2013
Highly Cited
2013
Thrombolytic therapy is the cornerstone of treatment of acute atherothrombotic ischemic stroke but is associated with brain… 
Highly Cited
2012
Highly Cited
2012
ALX-0681 is a therapeutic Nanobody targeting the A1-domain of VWF. It inhibits the interaction between ultra-large VWF and… 
Highly Cited
2011
Highly Cited
2011
Neutralizing the interaction of the platelet receptor gpIb with VWF is an attractive strategy to treat and prevent thrombotic… 
2011
2011
Compound ALX-0081 is a bivalent humanised Nanobody® that binds the A1-domain of von Willebrand factor (VWF) with high affinity… 
Review
2010
Review
2010
Atherothrombotic events, such as acute coronary syndrome or stroke, are the result of platelet activation. Von Willebrand factor… 
2009
2009
ALX-0681 is a humanized bivalent Nanobody®, that binds to the A1 domain of von Willebrand factor (vWF) and hence blocks its… 
2002
2002
The positron lifetimes in the B2 intermetallic compounds Co100−XAlX (X=46.9 to 54.1) water-quenched, air- and furnace-cooled from…